Glimepirid Mylan

Glimepirid Mylan is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea class antidiabetic agent. It is supplied in tablet form (strength not specified) and is marketed in the European Union. Glimepirid Mylan works by stimulating insulin release from pancreatic beta cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus as part of a comprehensive diabetes management plan.

Glimepirid Mylan is indicated for the oral management of hyperglycemia in patients with type 2 diabetes mellitus, typically when diet, exercise, and other oral agents are insufficient.

- As monotherapy in adults with type 2 diabetes when lifestyle changes alone do not achieve glycemic targets. - In combination with metformin to improve glycemic control. - As part of a multi‑drug regimen that may include other oral antidiabetics such as DPP‑4 inhibitors. - For patients who require a once‑daily sulfonylurea to simplify dosing. - To assist in achieving HbA1c reductions as recommended by clinical guidelines.

Side effects reported with glimepiride vary in frequency and severity.

Common: - Low blood sugar (hypoglycemia) especially if meals are missed. - Weight gain. - Nausea or abdominal discomfort. - Headache.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as rash, itching, or swelling. - Liver enzyme elevations. - Blood cell disorders (e.g., leukopenia, thrombocytopenia).

Before starting Glimepirid Mylan, healthcare providers should evaluate several safety considerations.

- Assess renal and hepatic function, as impairment may affect drug clearance. - Review history of hypoglycemia or adrenal insufficiency. - Use cautiously in elderly patients due to increased hypoglycemia risk. - Avoid use during pregnancy or breastfeeding unless benefits outweigh risks. - Monitor blood glucose regularly to adjust therapy. - Consider cardiovascular status, as sulfonylureas may influence heart disease risk.

Glimepirid Mylan can interact with other medicines, altering its effectiveness or safety profile.

Avoid: - Concurrent use with other sulfonylureas or insulin, which can cause additive hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that increase glimepiride plasma levels.

Use with caution: - Beta‑blockers, which may mask hypoglycemia symptoms. - Thiazide diuretics, which can raise blood glucose. - Certain antibiotics (e.g., quinolones) that may affect glucose control. - NSAIDs, which can potentiate hypoglycemic effects.